GlaxoSmithKline Pharmaceuticals Ltd Forays into Oncology with Jemperli & Zejula, Bringing Precision Therapies for Gynaecological Cancers
GlaxoSmithKline Pharmaceuticals Ltd has announced the availability of Jemperli (dostarlimab) and Zejula (niraparib) in India, marking its commitment to addressing the unmet need for specialised treatments in cancer care. Jemperli is the first and only approved PD-1 immunotherapy for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer, while Zejula is the only once-daily oral PARP inhibitor approved in India as first line monotherapy maintenance for all biomarker types in advanced ovarian cancer. The company has also introduced 'Phoenix', a Patient Support Program, to empower patients to access these innovative therapies. The molecules are supported by robust global clinical evidence and approvals from over 40 countries including the US, UK and EU.
Key Highlights
- GlaxoSmithKline Pharmaceuticals Ltd forays into Oncology in India with Jemperli and Zejula
- Jemperli is India’s first and only approved PD-1 immunotherapy for second-line treatment of dMMR/MSI-H advanced endometrial cancer
- Zejula is the only once-daily oral PARP inhibitor approved in India as first line monotherapy maintenance for all biomarker types in advanced ovarian cancer
- GSK introduces ‘Phoenix’, a Patient Support Program to empower patients to access these innovative therapies
- Jemperli and Zejula are supported by robust global clinical evidence and approvals from over 40 countries including the US, UK and EU